Page last updated: 2024-10-24

verapamil and Degenerative Diseases, Central Nervous System

verapamil has been researched along with Degenerative Diseases, Central Nervous System in 4 studies

Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.

Research Excerpts

Excerpt	Relevance	Reference
" The CCBs nimodipine (NDP) and verapamil (VPM) both significantly suppressed toxic secretions from human astrocytes and astrocytoma U-373 MG cells that were induced by interferon (IFN)-γ."	1.38	Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. ( Hashioka, S; Klegeris, A; McGeer, PL, 2012)

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bartels, AL	1
de Klerk, OL	1
Kortekaas, R	1
de Vries, JJ	1
Leenders, KL	1
Hashioka, S	1
Klegeris, A	1
McGeer, PL	1
Sarang, SS	1
Yoshida, T	1
Cadet, R	1
Valeras, AS	1
Jensen, RV	1
Gullans, SR	1
Doyle, KM	1
Kirby, BP	1
Murphy, D	1
Shaw, GG	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608]				29 participants (Actual)	Interventional	2015-05-31	Terminated (stopped due to Evidence that the dose is insufficient.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Diastolic Blood Pressure

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements

Intervention	mmHg (Mean)
Treatment	-0.6
Control	1

Heart Rate

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements.

Intervention	beats per minute (Mean)
Treatment	-1.4
Control	4

Objective Sinonasal Symptoms on Lund-Kennedy Score(LKS)

Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Intervention	units on a scale (Least Squares Mean)
Treatment	-1.3
Control	-0.25

Objective Sinonasal Symptoms on Lund-McKay Score(LMS)

Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8

Intervention	units on a scale (Mean)
Treatment	12.5
Control	17.7

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Intervention	units on a scale (Least Squares Mean)
Treatment	-44.03
Control	-6.07

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8

Intervention	units on a scale (Least Squares Mean)
Treatment	-27.3
Control	0.4

Systolic Blood Pressure

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements

Intervention	mmHg (Mean)
Treatment	-4.5
Control	-6.6

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56

Intervention	units on a scale (Mean)
	Medicine Completers, baseline	Medicine Completers, week 56	Surgical Completers, baseline	Surgical Completers, week 12
Open Label	64.3	35.0	90.0	16.7

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56

Intervention	units on a scale (Mean)
	Medicine Completers, baseline	Medicine Completers, week 56	Surgical Completers, baseline	Surgical Completers, week 12
Open Label	31.8	24.14	72.00	8.00

Reviews

1 review available for verapamil and Degenerative Diseases, Central Nervous System

Article	Year
11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease. Current topics in medicinal chemistry, 2010, Volume: 10, Issue:17 Topics: Aging; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain Diseases;	2010

Other Studies

3 other studies available for verapamil and Degenerative Diseases, Central Nervous System

Article	Year
Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. Neuropharmacology, 2012, Volume: 63, Issue:4 Topics: Astrocytes; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Cells, Cultured; Chemokin	2012
Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiological genomics, 2002, Oct-29, Volume: 11, Issue:2 Topics: Biological Assay; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulatio	2002
Effect of L-type calcium channel antagonists on spermine-induced CNS excitation in vivo. Neuroscience letters, 2005, Jun-03, Volume: 380, Issue:3 Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Central Nervous System; Convuls	2005